top of page

​Technology introduction

Technology of NOVIGO Pharma

We are developing transdermal administration technology, which makes it possible to administer drugs easily by absorbing them through the skin, and cell transfection technology, which introduces drugs into cells and extracellular vesicles, in order to reduce the burden on patients, which is a problem with injections and oral administration, and we are aiming to deploy these technologies on these platforms.

ウイルス研究

【Transdermal Administration Technology】
The skin has a barrier function to prevent foreign substances (such as bacteria and viruses) from penetrating the skin, so applying medicines to the skin alone does not provide enough effect.

However, we have succeeded in improving skin absorption by utilising Solid-in-Oil (S/O™) technology developed with Kyushu University.

【Cell Transfection Technology】
In general, cells are partitioned by cell membranes, which normally limit the entry and exit of substances, making it difficult to deliver drugs (especially high molecular weight drugs) into the cell.
The nanoparticulation technology using ionic lipids developed by our company has succeeded in efficiently introducing nucleic acids, proteins and other such active ingredients into cells and extracellular vesicles.

Solid-in-Oil (S/O) technology 

​TM

 S/O™ technology is comprised on a process of coating hydrophilic drugs with surfactants and dispersing them in oil as small particles of ten to hundreds of nanometres.
 The barrier function of the skin is formed by a lipophilic membrane called the stratum corneum, therefore drugs dispersed in oil are efficiently absorbed into the skin.
S/O™ technology is applicable to drugs with large molecular sizes, such as peptides, which can enhance the transdermal absorption of drugs.
 We are further improving our S/O™ technology to enhance its performance and conduct research into the practical application of more patient-friendly pharmaceuticals.

スクリーンショット 2021-04-10 19.17.02.png

Nanoparticulation technology using ionic lipids

 In this method, drugs are combined with ionic lipids to produce small particles of tens to hundreds of nanometers, which increase their affinity to the cell membrane and deliver the drugs efficiently into the cell. Conventional methods cannot introduce nucleic acids and protein drugs into cells, whereas our technology makes it possible to functionalise cells in cell therapy.
  This method can also be used to introduce active ingredients into extracellular vesicles (EVs), which is less toxic than viruses and other introduction methods, and provides a simple and efficient way to encapsulate.
 EVs are a new modality that is attracting attention as a natural drug delivery carrier, as they can be transported to and treated in target organs, which is difficult to deliver and treat with conventional artificial DDS.

 Our company also conducts research into the practical application of EVs as a DDS for drug discovery, utilising their properties.

ILB.png
bottom of page